Telix Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI
The ESG rating includes seventeen United Nations SDGs including: 'Gender Equality', 'Sustainable Cities & Communities' and 'Peace, Justice & Strong Institutions'. If you work at Telix Pharmaceuticals Ltd and you would like to use your Sustainability rating, please get in touch. The article includes a Q&A section on Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 4.0, social score of 8.0 and governance score of 8.0.
6.7
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
314 | Trulieve Cannabis Corp | 6.8 | High |
314 | Vicore Pharma Holding AB | 6.8 | High |
337 | Telix Pharmaceuticals Ltd | 6.7 | High |
337 | Calyxt Inc | 6.7 | High |
337 | CanSino Biologics Inc | 6.7 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Telix Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Telix Pharmaceuticals Ltd disclose current and historical energy intensity?
Does Telix Pharmaceuticals Ltd report the average age of the workforce?
Does Telix Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?
Does Telix Pharmaceuticals Ltd disclose its ethnicity pay gap?
Does Telix Pharmaceuticals Ltd disclose cybersecurity risks?
Does Telix Pharmaceuticals Ltd offer flexible work?
Does Telix Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Telix Pharmaceuticals Ltd disclose the number of employees in R&D functions?
Does Telix Pharmaceuticals Ltd conduct supply chain audits?
Does Telix Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Telix Pharmaceuticals Ltd conduct 360 degree staff reviews?
Does Telix Pharmaceuticals Ltd disclose the individual responsible for D&I?
Does Telix Pharmaceuticals Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Telix Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?
Does Telix Pharmaceuticals Ltd disclose water use targets?
Does Telix Pharmaceuticals Ltd have careers partnerships with academic institutions?
Did Telix Pharmaceuticals Ltd have a product recall in the last two years?
Does Telix Pharmaceuticals Ltd disclose incidents of discrimination?
Does Telix Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?
Has Telix Pharmaceuticals Ltd issued a profit warning in the past 24 months?
Does Telix Pharmaceuticals Ltd disclose parental leave metrics?
Does Telix Pharmaceuticals Ltd disclose climate scenario or pathway analysis?
Does Telix Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Telix Pharmaceuticals Ltd disclose the pay ratio of women to men?
Does Telix Pharmaceuticals Ltd support suppliers with sustainability related research and development?
Does Telix Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Telix Pharmaceuticals Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Telix Pharmaceuticals Ltd involved in embryonic stem cell research?
Does Telix Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?
Does Telix Pharmaceuticals Ltd disclose its waste policy?
Does Telix Pharmaceuticals Ltd report according to TCFD requirements?
Does Telix Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Telix Pharmaceuticals Ltd disclose energy use targets?
Does Telix Pharmaceuticals Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Telix Pharmaceuticals Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Telix Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.